Rapid diagnostic tests relating to antibiotic resistance and methods of use and preparation thereof

Through a biochemical system with dual enzyme triggered cascade technology, the diagnosis of antibiotic-resistant bacteria in urinary tract infections is solved in the prior art with a targeted small molecule probe and enzyme amplifier. Improves the efficiency and accuracy of urinary tract infection treatment.

CN119096144APending Publication Date: 2024-12-06BIOAMP DIAGNOSTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380025317.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-28
Filing Date
2023-01-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to quickly and accurately diagnose antibiotic-resistant bacteria in urinary tract infections, especially multi-drug-resistant urinary tract infections, resulting in delayed treatment and inappropriate use of antibiotics.

Method used

Using a biochemical system based on dual enzyme triggered cascade technology (DETECT), small molecule indicators that release chromophores are activated by targeting small molecule probes and enzyme amplifiers to generate chromogenic signals to indicate antibiotic sensitivity or resistance. Achieve rapid diagnosis.

Benefits of technology

Provide antibiotic-sensitive results within minutes, improve diagnostic efficiency and accuracy of urinary tract infections, reduce misuse of drug-resistant bacteria, and is suitable for a wide range of medical settings, including clinical, family and rural medical facilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119096144A_ABST
    Figure CN119096144A_ABST
Patent Text Reader

Abstract

Urinary tract infections (UTIs) are still one of the most common global bacterial infections, which have increasingly strong resistance to many first-line antibiotics commonly used to treat these infections. Multi-drug resistant bacteria are only limited to the walls of hospitals, but are rampant in communities at present. Provided herein are reagent tests and methods of use thereof that can be used to identify specific types of antibiotic resistant microorganisms in a sample.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority under 35 U.S.C. §119 to provisional application serial number 63 / 304,335 filed on January 28, 2022, the disclosure of which is incorporated herein by reference. Technical Field

[0003] Provided herein are test methods, systems, and kits that can be used to identify specific types of antibiotic-resistant microorganisms in a sample. Background Art

[0004] Urinary tract infections (UTIs) remain one of the most common bacterial infections worldwide, and they are becoming increasingly resistant to many of the first-line antibiotics commonly prescribed to treat these infections. Multidrug-resistant bacteria, once confined within the walls of hospitals, are now rampant in the community. Recent clinical outcome studies have reported that >85% of patients seeking treatment for cUTIs caused by multidrug-resistant organisms are found in the community rather than in long-term healthcare or specialized care settings. Perhaps even more striking is the emergence of multidrug-resistant UTIs in infants and children under 5 years of age. In general, there is an urgent need for diagnostic tests that can allow for evidence-based treatment of UTIs to avoid the selection pressures imposed by current empirical treatment practices, which have resulted in highly drug-resistant bacterial pathogens. Therefore, there is a need for diagnostic tests that can be performed across a wide range of healthcare settings to meet the emerging needs of the increased impact of UTIs witnessed by patients and healthcare systems. Diagnostic tests that can provide the clinical information needed to guide UTI care must (1) be adaptable to a wide range of workflows, (2) be affordable, and (3) be capable of being performed by unskilled personnel. Summary of the invention

[0005] The present disclosure provides an overview of test components and systems that, alone or in combination, represent test options that can be used to guide UTI care in the clinic, in a practitioner's office, for home use, or in a rural healthcare setting. In a specific embodiment, the present disclosure provides a biochemically driven dipstick test (U-DETECT) to support antibiotic therapy selection for complicated urinary tract infections (cUTIs). While there are several existing and emerging technologies that are intended to provide antibiotic sensitivity results within hours, U-DETECT is a diagnostic test that is capable of generating sensitivity results within minutes by utilizing a biochemical system called DETECT (Dual-Enzyme Trigger-Enabled Cascade Technology). DETECT is a two-layer system designed to identify the presence of low-abundance enzymes produced by bacteria that enable them to avoid the therapeutic effects of antibiotics. The targeting layer Tier-1 of DETECT is composed of small molecule probes (sometimes referred to as targeting probes) that mimic antibiotic scaffolds used as first-line therapy for UTIs. If the UTI is caused by drug-resistant bacteria (uropathogens), the targeted probe will be hydrolyzed and release the trigger unit, which will trigger the signaling layer (Tier-2) of DETECT, generating a chromogenic signal output. The chromogenic signal generated by DETECT is similar to the bacterial growth observed using standard antibiotic sensitivity testing, indicating the presence of resistant infection to a given antibiotic by color signal generation, while the absence of color will indicate sensitivity. The present disclosure provides a rapid diagnostic test strip dip test for detecting antibiotic-resistant bacteria using DETECT, as well as methods of use and manufacturing thereof.

[0006] In a specific embodiment, the present disclosure provides a solid substrate comprising a reagent or component for measuring the presence of β-lactamase produced by Gram-negative, Gram-positive or pathogenic β-lactam-resistant bacteria, which includes a first pad on a solid substrate, which includes a targeted small molecule probe specifically acted upon by β-lactamase; a caged enzyme amplifier; and a small molecule indicator that releases a chromophore activated by a non-caged enzyme amplifier. In another embodiment, the solid substrate includes a second pad on a solid substrate, which includes a caged enzyme amplifier; and a small molecule indicator that releases a chromophore activated by a non-caged enzyme amplifier, wherein the second pad does not include a targeted small molecule probe, optionally, a third pad or more pads comprising reagents or components on the solid substrate. In another or further embodiment, the components of the first pad and / or the second pad are dry. In another or further embodiment, the first pad, the second pad, and the optional third pad or more pads include an adsorbent or plastic material. In a further embodiment, the adsorbent material is selected from paper, an adsorbent polymer, silica gel, glass fiber, zeolite or fabric. In yet a further embodiment, the paper is selected from cellulose, nitrocellulose, Teslin or filter paper. In another embodiment, the plastic material is selected from high-density polyethylene (HDPE), low-density polyethylene (LDPE), polypropylene (PP), polyvinyl chloride (PVC), polycarbonate (PC), polysulfone (PSF), polystyrene (PS), Teflon (FEP) or Teflon (PFA). In any of the foregoing embodiments, the solid matrix comprises paper or plastic. Still in another embodiment of any of the foregoing embodiments, the solid matrix is ​​a rectangular strip with a width of less than 10 mm. In another embodiment of any of the foregoing, the targeted small molecule probe comprises a β-lactam group. In another embodiment of any of the foregoing, when the targeted small molecule probe is acted upon by a β-lactamase, the targeted small molecule probe releases a thiophenol group, which interacts with the caged enzyme amplifier to be released from the cage and activate the enzyme amplifier. In yet a further embodiment of any of the foregoing, the caged enzyme amplifier is a caged cysteine ​​protease. In a further embodiment, the cysteine ​​protease is selected from papain, bromelain, cathepsin K, calpain, caspase-1, separase, adenovirus endopeptidase (adenain), pyroglutamyl peptidase I, sortase A, hepatitis C virus peptidase 2, Sindbis virus type nsP2 peptidase, dipeptidyl peptidase VI, deSI-1 peptidase, TEV protease, amidophosphoribosyltransferase precursor, γ-glutamyl hydrolase, hedgehog protein and dmpA aminopeptidase. In another embodiment of any of the foregoing, the caged enzyme amplifier is caged papain. In a further embodiment, the caged papain has the structure of papain-SS-CH3.In another embodiment of any of the foregoing, the small molecule indicator that releases the chromophore is N-benzoyl-DL-arginine-4-nitroaniline (BAPA) or a derivative thereof. In a further embodiment, the derivative of BAPA comprises a chromophore group different from the p-nitroaniline group. In a further embodiment, the derivative of BAPA comprises a dipeptide-X1X2- or a tripeptide-X1X2X3- to replace the arginine group of BAPA, wherein X1, X2 and X3 are each independently selected from any amino acid. In a further embodiment, at least one of X1 to X3 is a hydrophobic amino acid. In a further embodiment, one of X1 to X3 is phenylalanine. In another embodiment of any of the foregoing embodiments, when subjected to the action of an enzyme amplifier, the chromophore is released from the small molecule indicator that releases the chromophore. In a further embodiment, the chromophore absorbs light with a wavelength of 350nm to 900nm. In a further embodiment, the chromophore is p-nitroaniline and absorbs light with a wavelength of about 405nm. In another or further embodiment, the chromophore absorbs light at a wavelength of 520 nm to 600 nm. In a further embodiment, the chromophore is resorufin. In another embodiment of any of the foregoing, the solid substrate includes a third pad attached to the solid substrate, which includes an enzyme amplifier; and a small molecule indicator that releases the chromophore activated by the enzyme amplifier. In another or further embodiment of any of the foregoing, the solid substrate includes a fourth pad attached to the solid substrate, which includes a reagent or component, including a small molecule indicator that releases the chromophore activated by the enzyme amplifier.

[0007] The present disclosure also provides a solid substrate comprising a reagent or component for measuring the presence of a β-lactamase produced by a Gram-negative, Gram-positive or pathogenic β-lactam-resistant bacteria, comprising a solid substrate having the following: (a) a first region or layer comprising a targeted small molecule probe selected from (i) a β-lactamase-acted target; (ii) a caged enzyme amplifier; and (iii) one or two components of a small molecule indicator that releases a chromophore; and (b) a second region or layer comprising (i), (ii) and / or (iii) that are not present in the first region. In one embodiment, the first region and the second region are linearly separated from each other along the path followed by the wicking liquid (e.g., a lateral flow assay system). In another embodiment, the first region and the second region are stacked on each other. In another or further embodiment, the solid substrate comprises a third region having a caged enzyme amplifier; and a small molecule indicator that releases a chromophore, but does not comprise a targeted small molecule probe; optionally, a fourth region or more regions comprising a reagent or component on the solid substrate. In another or further embodiment, the components of the first region, the second region or the third region are dry. In another or further embodiment, the components of the first region, the second region or the third region are absorbed or adsorbed to a solid substrate or a material attached thereto. In a further embodiment, the solid support or material is selected from paper, an adsorbent polymer, plastic silica gel, glass fiber, zeolite or fabric. In yet another further embodiment, the paper is selected from cellulose, nitrocellulose, Teslin or filter paper. In yet another further embodiment, the plastic material is selected from high-density polyethylene (HDPE), low-density polyethylene (LDPE), polypropylene (PP), polyvinyl chloride (PVC), polycarbonate (PC), polysulfone (PSF), polystyrene (PS), Teflon (FEP) or Teflon (PFA). Also in another embodiment of any of the aforementioned embodiments, the solid substrate is a rectangular strip with a width of less than 10 millimeters. In another embodiment of any of the aforementioned embodiments, the targeted small molecule probe comprises a β-lactam group. In another embodiment of any of the aforementioned embodiments, when the targeted small molecule probe is acted upon by β-lactamase, the targeted small molecule probe releases a thiophenol group, which interacts with the caged enzyme amplifier to release and activate the enzyme amplifier from the cage. In yet further embodiments of any of the foregoing, the caged enzyme amplifier is a caged cysteine ​​protease. In a further embodiment, the cysteine ​​protease is selected from the group consisting of papain, bromelain, cathepsin K, calpain, caspase-1, separase, adenovirus endopeptidase, pyroglutamyl peptidase I, sortase A, hepatitis C virus peptidase 2, Sindbis virus type nsP2 peptidase, dipeptidyl peptidase VI, deSI-1 peptidase, TEV protease, amidophosphoribosyltransferase precursor, gamma-glutamyl hydrolase, hedgehog protein, and dmpA aminopeptidase.In another embodiment of any of the foregoing, the caged enzyme amplifier is a caged papain. In a further embodiment, the caged papain has the structure of papain-SS-CH3. In another embodiment of any of the foregoing, the small molecule indicator that releases the chromophore is N-benzoyl-DL-arginine-4-nitroaniline (BAPA) or a derivative thereof. In a further embodiment, the derivative of BAPA contains a chromophore group different from the p-nitroaniline group. In yet another further embodiment, the derivative of BAPA contains a dipeptide-X1X2- or a tripeptide-X1X2X3- to replace the arginine group of BAPA, wherein X1, X2 and X3 are each independently selected from any amino acid. In yet another further embodiment, at least one of X1 to X3 is a hydrophobic amino acid. In a further embodiment, one of X1 to X3 is phenylalanine. In another embodiment of any of the foregoing, when subjected to the enzyme amplifier, the chromophore is released from the small molecule indicator that releases the chromophore. In a further embodiment, the chromophore absorbs light at a wavelength of 350 nm to 900 nm. In a further embodiment, the chromophore is p-nitroaniline and absorbs light at a wavelength of about 405 nm. In another or further embodiment, the chromophore absorbs light at a wavelength of 520 nm to 600 nm. In a further embodiment, the chromophore is resorufin.

[0008] The present disclosure also provides a method for measuring the presence of β-lactamase produced by a pathogen in a sample, comprising: contacting a solid substrate as shown in any one of the embodiments described above with a sample, and measuring the absorbance at a wavelength of 400nm to 600nm, wherein the absorbance change of the solid substrate measured indicates the presence of β-lactamase produced by the pathogen in the sample. In one embodiment, the β-lactamase is selected from TEM-1, SHV-1, CTX-M-14, CTX-M-15, CMY-2 and KPC-2. In another or further embodiment, the pathogen is Escherichia coli (E.coli), Klebsiella pneumoniae (K.pneumoniae), Pseudomonas aeruginosa (Pseudomonas aeruginosa) and / or Proteus mirabilis (P.mirabilis). In another embodiment, the sample is from a subject. In another embodiment, the sample is a urine or blood sample. In a further embodiment, the sample is a urine sample from a subject suspected of having a urinary tract infection.

[0009] In other embodiments of the present disclosure, a solid substrate or method as described herein comprises a targeted small molecule probe having the general structure of Formula I:

[0010]

[0011] Formula (I)

[0012] or a salt, stereoisomer, tautomer, polymorph or solvate thereof, wherein: T 1 is a group containing benzenethiol; Z 1 is a carboxylate, a carbonyl or an ester; X 1 yes Y 1 yes R 1 -R 6 R is each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl and optionally substituted heterocycle; 7 is optionally substituted (C5-C7)cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle. In a further embodiment, T 1 is a benzenethiol group selected from:

[0013] In another embodiment, R 7 Select from the following:

[0014] In yet another embodiment, the compound has the structure of Formula I(a):

[0015]

[0016] or a salt, stereoisomer, tautomer, polymorph or solvate thereof, wherein: T 1 is a group containing benzenethiol; Z 1 is a carboxylate, a carbonyl or an ester; X 1 yes Y 1 yes R 1 -R 6 R is each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl and optionally substituted heterocycle; 7is optionally substituted (C5-C7)cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle. In a further embodiment, T 1 is a benzenethiol group selected from:

[0017] In yet a further embodiment, R 7 Select from the following:

[0018] In yet another embodiment, the compound has the structure of Formula I(b):

[0019]

[0020] X 1 yes Y 1 yes R 1 -R 6 R is each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl and optionally substituted heterocycle; 7 is optionally substituted (C5-C7)cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle. In a further embodiment, T 1 is a benzenethiol group selected from:

[0021] In a further embodiment, R 7 Select from the following:

[0022] In an additional or further embodiment of any of the foregoing, the targeted small molecule probe comprises a compound selected from the group consisting of:

[0023]

[0024] , or a salt, stereoisomer, tautomer, polymorph or solvate thereof.

[0025] The invention covers all combinations of specific embodiments described herein, as if each combination were exhaustively described.

[0026] The details of one or more embodiments of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1A -B provides an overview of one embodiment of (A) DETECT assay, which can be applied to directly reveal CTX-M β-lactamase activity in clinical urine samples. A representative experimental workflow is applied to analyze urine samples by DETECT. A small amount of urine is transferred to a well containing DETECT reagent (D; steps 1 and 2). The absorbance at 405 nm is recorded with a spectrophotometer at 0 minutes (A 405nm If the target resistance marker (E1; CTX-M ESBL enzyme) is present, the targeted probe is hydrolyzed and the thiophenol trigger is eliminated from the probe, subsequently activating the amplification and colorimetric signal output layer of DETECT (step 3). After 30 minutes of room temperature incubation, A is recorded again. 405nm Read the data and calculate the DETECT score (step 4; A 405nm T30-T0). A DETECT score above the experimentally determined threshold indicates that the sample contains the target CTX-M β-lactamase and, therefore, the presence of extended-spectrum cephalosporin-resistant GNB in ​​the urine sample (step 5). A DETECT score below the threshold indicates that the sample does not contain the target resistance marker. BAPA: Nα-benzoyl-L-arginine 4-nitroanilide hydrochloride. (B) Chemical structures of targeted probe options that can be used in the DETECT assay or as a dry reagent component; the use of reagents BAD-5385 (G2B) and BAD-5627 with sensitivity to β-lactamases as a measure of absorbance is shown.

[0028] Figure 2Embodiments and possible test results of components of U-DETECT test strips are shown. As shown, components that can be embedded / immersed in the "sample" pad are listed: sodium phosphate buffer system, Bis Tris buffer system, modified enzyme amplifier (e.g., cysteine ​​protease), indicator small molecules (e.g., N-benzoyl-L-arginine-nitroaniline or its derivatives) and BAD probe (defined as a small molecule probe molecule consisting of a thiophenol portion, which is selectively released by a complementary enzyme biomarker). All components can be prepared to 1-5-X concentration relative to the standard concentration of the liquid phase assay form applied to the test. Description of potential components that can be embedded / immersed in the "control" pad, the potential components are the same as the components described in the "sample" pad, except for the BAD probe. The pad is a solid support called "paper", wherein the "paper" can include, but is not limited to, nitrocellulose, cellulose, glass fiber, Teslin, filter paper, etc.

[0029] Figure 3A-H Embodiments of potential test strip formats are presented. (A) Each test requires a "blank" and "sample" pad to produce a result (+ / -). When the analyzer is applied to the reflectance or fluorescence of the measuring surface, a quantitative value can be obtained. The test is run, whereby the discernible difference in visual color, fluorescence or reflectance is greater in the "sample" pad relative to the "control" pad. AD represents a combination of positive and negative control pads that can be included in a complete test strip, where the "positive" pad will include a standard thiol trigger component and the "negative" pad excludes modified enzymes and small molecule biomarker targeting probes. (EF) In order to develop a test that can distinguish a family of target biomarkers (e.g., β-lactamases), an inhibitor compound can be incorporated into the test strip, as described in E. Spanning FH includes a combination of "positive" and "negative" control pads that can be included.

[0030] Figure 4 shows how the coating of "sample" and "control" can be performed by: preparing Figure 2 The "sample" solution is composed of the components described in the "sample" pad and Figure 2 A "control" solution consisting of the components described in the "sample" pad of the invention is applied to the surface of the "paper" pad using automated dispensing, a fabric or rubber stamp, a dropper, an inkjet printer or derivatives thereof, or a marker. Then, after applying the pad in parallel or in succession, a drying method is used, which may include, but is not limited to, forced air, freeze drying, or heat drying.

[0031] Figure 5An embodiment of the components requiring separation of aqueous compatible and incompatible components is shown, preparing two (2), three (3) or four (4) separate solution pairs coated on a "paper" pad. The sequence can be as follows: coating the "sample" organic solution on the sample paper pad, drying the sample pad, coating the "blank" organic solution on the blank paper pad, drying the control pad, coating the sample and blank aqueous solutions (which can also be prepared as one solution) simultaneously on the sample and control pads, followed by a final drying step. The figure also depicts a more general preparation option that can be used to prepare a coating or strips or wells.

[0032] Fig. 6A -B provides Figure 5 , regarding how coatings for a "sample," "control," or other type of pad may be applied sequentially (A) with a drying step after each set of coating applications, or simultaneously (B) and dried thereafter.

[0033] Figure 7 Provides an embodiment of a simplified workflow for applying liquid phase reagents (R1 and R2) to reagent pads and their subsequent drying, cutting and sticking steps

[0034] Figure 8A-B An overview of Study 1 and Study 2 and the corresponding solutions received by each strip is provided. Study 1 materials: papain, BAPA, BAD-5835 and cysteine ​​(100 μM). Study 2 materials: papain, BAPA, BAD-5835 and CTX-M-15 (1 nM or 4 nM). Left: Representation of each study and test strips representing control (buffer) and sample (cysteine ​​or CTX-M-15). Right: For each time point, the percent reflectance of the sample strip was subtracted from the control strips of Study 1 (A) and Study 2 (B).

[0035] Figure 9A-D Results are presented: (A) %R scores (%Reflectance Control - %Reflectance Sample) over time for Formulations 1-4 of Table 1. (B) DETECT %R scores (%R scores 20分钟 -% R-Rating 2分钟 (C) %R scores (%Reflectance Control - %Reflectance Sample) for Formulations 2 and 5-9 of Table 1 over time. (D) DETECT %R scores (%R scores) for Formulations 2 and 5-9 of Table 1 20分钟 -% R-Rating 2分钟 ).

[0036] Fig. 10A-DReflectance data for CTX-M-15 are presented for 1 nM (A) and (B); and 4 nM (C) and (D). Where %R score is %Reflectance Control - %Reflectance Sample for each time point. And DETECT %R score is %R score for formulations 7-9 of Table 1 20分钟 -% R-Rating 2分钟 .

[0037] Figure 11A-D shows the ability of tripeptide and dipeptide substrates to provide significant absorbance changes (DETECT scores) and maintain high signal-to-noise ratios (S / N) at 5 minutes. (A) Kinetic parameters for each papain substrate obtained at room temperature by adding cysteine ​​to activate papain and monitoring the absorbance increase at 405nm. (B) Absorbance changes observed from t=0 to t=5m after cysteine ​​activation of papain (DETECT scores), and (C) S / N, where signal is the absorbance generated in the presence of cysteine ​​and noise is the amount of signal absorbance generated in the absence of cysteine ​​papain activator. (D) Chemical structures of BAPA derivatives including dipeptide and tripeptide substrates Bz-FR and Bz-QFR are shown.

[0038] Figure 12A-C For each isolate (10 6 CFU / mL), DETECT score calculated for (A) DETECT 1.0 and (B) DETECT-BzFR. DETECT score was calculated by calculating the difference (AbsΔ 5分钟 -AbsΔ 0分钟 ) was determined. (C) For each isolate, the raw absorbance values ​​were used to calculate the % increase in signal relative to noise after 5 minutes of assay incubation. The noise used for this calculation is the amount of absorbance generated by the negative (SF505) isolate, where % increase = (Abs 信号 -Abs 阴性 ) / Abs 阴性 *100.

[0039] Fig.13 An example of a chromogenic probe for sulfite is provided, where a dramatic color is obtained when protected resorufin reacts with sulfite.

[0040] Figure 14A-B An overview of the transformations that BAPA derivatives will undergo to provide longer wavelength signaling molecules for papain is provided. (A) Bz-FR-pNA and (B) Bz-XX-pNa candidates are converted to their respective resorufin derivatives. XX = optimal amino acids (R1 and R2).

[0041] Figure 15A-B An overview of the synthetic scheme for obtaining azo-based chromophore derivatives is provided. (A) Where X = H, NO2, Cl or Br, and R1 = H, OCH3, SO3 - The NH2 group is highlighted to represent the reactive group for C-terminal modification. (B) Modification of the identified peptide backbone Bz-XX-COOH to generate the derivative BAPA-Azo papain substrate.

[0042] Figure 16A-B Presented are (A) the proposed indoleaniline chromophore scaffold to be synthesized and characterized. (B) Modification of the identified peptide backbone Bz-XX-COOH to generate the derivative BAPA-Indo papain substrate. DETAILED DESCRIPTION

[0043] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a β-lactamase substrate" includes a plurality of such substrates and reference to "the β-lactamase" includes reference to one or more β-lactamases and equivalents thereof known to those skilled in the art, and so forth.

[0044] Additionally, the use of "or" means "and / or" unless otherwise stated. Similarly, "comprise," "comprises," "comprising," "include," "includes," and "including" are interchangeable and are not meant to be limiting.

[0045] It should be further understood that while the description of various embodiments uses the term “comprising,” those skilled in the art will appreciate that, in some specific cases, the embodiments may alternatively be described using the language “consisting essentially of” or “consisting of.”

[0046] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.Exemplary methods and materials are disclosed herein, although many methods and reagents are similar or equivalent to those described herein.

[0047] All publications mentioned herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing methodologies that might be used in conjunction with the description herein. In addition, for terms expressly defined in this disclosure, the definitions of those terms as expressly set forth in this disclosure will control in all respects, even if the term has been given a different meaning in a publication, dictionary, treatise, or the like.

[0048] Gram-negative bacteria (GNB) that produce extended-spectrum β-lactamases (ESBLs) express enzymes that hydrolyze and inactivate most β-lactam antibiotics, including penicillins, cephalosporins, extended-spectrum cephalosporins (including third- and fourth-generation agents), and monobactams. The Centers for Disease Control and Prevention (CDC) designated ESBL-producing Enterobacteriaceae as a "serious threat" in its 2013 and 2019 Antibiotic Resistance Threats reports, and the World Health Organization designated it as a "key priority" in its 2017 Global Priority List of Antibiotic-Resistant Bacteria. In 2017, there were an estimated 197,400 ESBL-producing Enterobacteriaceae infections in hospitalized patients in the United States, resulting in 9,100 deaths and $1.2 billion in attributable health care costs. ESBL infections represent a significant public health problem—infections occur in both healthcare and community settings, and their incidence is increasing in the United States and worldwide.

[0049] Due to its low toxicity and effectiveness against a range of clinically relevant bacteria, β-lactams are one of the most important classes of antibiotics, accounting for ~ 50% of total antibiotic prescriptions worldwide. This class of antibiotics consists of several generations of variants, the difference of which is only in the chemical side chains decorated by the two centers (C3 and C7) across the β-lactam pharmacophore. The resistance mechanism that has evolved in bacteria to avoid the therapeutic effects of β-lactams is through the production of β-lactamases, which work by hydrolyzing the β-lactam pharmacophore. Interestingly, there are thousands of β-lactamase variants, which are grouped and classified by the phenotypic resistance caused by their expression. For example, the first generation of β-lactamases (such as TEM-1, SHV-1 and OXA-1) are grouped and defined according to their ability to produce resistance to early generation β-lactams. Like this, uropathogens that produce first generation β-lactamases will be resistant to the earliest generation of β-lactams such as ampicillin.

[0050] The clinical management of cUTI has become increasingly problematic due to the increasing incidence of antibiotic-resistant bacteria called extended-spectrum β-lactamase (ESBL)-producing uropathogens (~15-20% incidence across the United States), which are resistant to ceftriaxone (a third-generation β-lactam), the first-line therapy for cUTI. In addition, ESBL-uropathogens are often multidrug resistant (MDR), further reducing the treatment options for these infections. In a retrospective study in collaboration with Kaiser Permanente, the impact of delays in the diagnosis of ESBL-associated cUTI was elucidated. In this study, a cohort of patients was divided into ESBL-associated (cases) versus non-ESBL-associated cUTI (controls) groups to investigate the impact of ESBL-producing uropathogens (Escherichia coli and Klebsiella) on the outcomes of patients hospitalized for cUTI. It was observed that 63% of ESBL-associated cUTIs were treated with "inappropriate" first-line therapy, resulting in 1.2 times the length of hospital stay of patients with non-ESBL cUTIs, and a 33% higher mortality rate (65 / 530 cases vs. 279 / 3,577 controls). Given that there is no precedent for increased virulence of ESBL-producing organisms, the single factor attributed to the worse outcomes in the case group relative to the control group is the delay in time to diagnosis. Therefore, a diagnostic test that can immediately identify ESBL-associated cUTIs to establish appropriate treatment would produce better outcomes for patients experiencing cUTIs. In addition, 16% of non-ESBL-associated cUTIs were unnecessarily treated with broad-spectrum carbapenems, a class of last resort antibiotics that are typically reserved for serious infections that have few other treatment options.

[0051] The present disclosure provides the use of DETECT assay in a reagent test strip format (e.g., a dry reagent test strip format). As shown in Figure 1, DETECT is a solution-based assay that utilizes an amplification technique with a dual enzyme cascade. In particular, DETECT uses a targeted probe to target a resistance marker (E1; CTX-M ESBL enzyme), and if the target resistance marker is present, the targeted probe is hydrolyzed and the thiophenol trigger is eliminated from the probe, subsequently activating the amplification and colorimetric signal output layer of DETECT. DETECT has been used to identify ESBL-producing uropathogens directly from untreated clinical urine samples as an alternative to ceftriaxone and cefotaxime resistance / sensitivity. In a double-blind study, 472 clinical urine samples were analyzed by liquid phase testing and the diagnostic performance of DETECT was confirmed to be 90.9% sensitivity and 97.6% specificity, with a negative predictive value (NPV) of 99.7 and a positive predictive value (PPV) of 45.4% (AUC 0.937; 95% confidence interval, 0.822-1.000). These results correlated with the clinical reference standard of bacterial culture and antibiotic susceptibility testing (C&S).

[0052] The introduction of dry reagent test strips in the 1950s completely changed the way of clinical testing. The test routinely performed in clinical chemistry laboratories was transferred to other health care departments, such as doctors' offices, outpatient clinics and even at home by patients. This evolution is attributed to the success of the first semi-quantitative urine glucose test strip, which set a precedent for the development of test strips for other analytes (protein, ketone, bilirubin, nitrite, esterase and pH) found in urine, and the test strips have now become the standard practice for the multi-experimental panel test of urinalysis. The low cost and simplicity of dry reagent test strips are the fundamental reasons for its widespread adoption. In addition, these tests can be performed directly to patient urine samples by unskilled users, and their results are produced in less than 5 minutes.

[0053] The manufacture of dry reagent test strips involves the controlled addition of reagents (i.e., indicator dyes, enzymes, small molecule probes, polymers, etc.) to a solid matrix (e.g., cellulose) and the drying by heating. After the drying process, the solid matrix is ​​bonded to a plastic support with an adhesive, which allows the test to be carried by the user and immersed in the target sample (alternatively, the sample can be added to the reagent pad). The result is then read on a reflective spectrophotometer instrument. Several enzymatic assays (solution phase) are converted into dry reagent test strips, which have provided several advantages over the assay form, such as convenient, reduced minimum storage requirements (i.e., cold chain) and improved reagent stability in some cases. In addition, dry reagent test strips eliminate the multi-step procedure that usually requires a skilled user, allowing results to be obtained with minimal processing steps. Economically, reagent test strips are cost-effective, and only require a portable reflective instrument (for quantitative measurement). It is well known that some assay reagents may be too unstable to undergo a manufacturing process, and the development of reagent test strips needs to be optimized.

[0054] Therefore, the dry reagent test strips disclosed herein (e.g., U-DETECT) not only provide improved results for patients and subjects, but will also support the reduction of the use of broad-spectrum antibiotics, which can lead to the spread of infections resistant to last resort antibiotic agents. In a specific embodiment, the dry reagent test strips disclosed herein include a small molecule probe that releases thiophenol, an enzyme amplifier (e.g., a cysteine ​​protease), and a small molecule indicator that releases a chromophore activated by the enzyme amplifier. Specific examples of targeted small molecule probes that release thiophenol are described in PCT / US2020 / 048060, the disclosure of which is incorporated by reference in its entirety. Further examples of targeted small molecule probes include those described in the Examples section, including, but not limited to: (7R)-7-(2-(1H-tetrazol-1-yl)acetamido)-8-oxo-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-5835), (7R)-7-(3-methylisoxazole-5-carboxamido)-8-oxo-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-1468), (7R)-8-oxo-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-1468). 0] oct-2-ene-2-carboxylic acid (BAD-3462), (7R)-8-oxo-7-(2-phenoxyacetylamino)-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-7465). For example, the small molecule probe releasing thiophenol can have the structure of Formula I:

[0055]

[0056] or a salt, stereoisomer (in some cases, a structural isomer), tautomer, polymorph or solvate thereof, wherein: T 1 is a group containing benzenethiol; Z 1 is a carboxylate, a carbonyl or an ester; X 1 yes

[0057] Y 1 yes R 1 -R 6R is each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl and optionally substituted heterocycle; 7 is optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle. In another embodiment or a further embodiment of any of the foregoing embodiments, T 1 is a benzenethiol group selected from:

[0058] In another embodiment or a further embodiment of any of the foregoing embodiments, R 7 Selected from

[0059] In another embodiment or a further embodiment of any of the foregoing embodiments, the compound has the structure of Formula I(a):

[0060]

[0061] or a salt, stereoisomer, tautomer, polymorph or solvate thereof, wherein: T 1 is a group containing benzenethiol; Z 1 is a carboxylate, a carbonyl or an ester; X 1 yes

[0062] Y 1 yes R 1 -R 6 R is each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl and optionally substituted heterocycle; 7 is optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle. In another embodiment or a further embodiment of any of the foregoing embodiments, T 1 is a benzenethiol group selected from:

[0063] In another embodiment or a further embodiment of any of the foregoing embodiments, R 7 Selected from

[0064] In another embodiment or a further embodiment of any of the foregoing embodiments, the compound has the structure of Formula I(b):

[0065]

[0066] X 1 yes

[0067] Y 1 yes R 1 -R 6 R is each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl and optionally substituted heterocycle; 7 is optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle. In another embodiment or a further embodiment of any of the foregoing embodiments, T 1 is a benzenethiol group selected from:

[0068] In another embodiment or a further embodiment of any of the foregoing embodiments, R 7 Selected from

[0069]

[0070] In another embodiment or a further embodiment of any of the foregoing embodiments, the compound is selected from the group consisting of:

[0071]

[0072] , or a salt, stereoisomer, tautomer, polymorph or solvate thereof.

[0073] In another embodiment, the dry reagent test strip disclosed herein comprises at least two (2) test pads impregnated with a reagent assay component that can together detect the presence of an enzyme biomarker, such as β-lactamase, esterase, cysteine ​​protease, etc. In a further embodiment, the dry reagent test strip comprises 2, 3, 4, 5, 6 or 7 test pads, or a series of test pads including or between any two of the foregoing. Examples of different types of test pads can include a positive control, a negative control, a sample test pad, a control test pad lacking a probe, a second, third or fourth control test pad comprising a reagent assay component that comprises a different probe. In a further embodiment, the present disclosure also provides a dry reagent test strip that can be read by eye or with a detector device. Examples of detector devices include, but are not limited to, an automated analyzer device, a digital device, a color sensor, or a manual handheld device capable of detecting visible wavelengths in the range of 350-950 nm. In yet another further embodiment, the automated analyzer device is a simple urine strip analyzer (e.g., Siemens Clinitek TM In another embodiment, the reagent test components are applied to the test pad of a dry reagent test strip. In a further embodiment, the reagent test components are combined or individually contained in a solution phase in a reagent container. In yet a further embodiment, the reagent test components are incorporated into an automated dispensing system. In another embodiment, the reagent test components are lyophilized, stamped, chemically or physically trapped, or coated onto a solid surface (paper, plastic, or porous tray).

[0074] The dry reagent test strips and methods of the present disclosure have the following characteristics: the determination is fast and easy to perform, and no urine processing step is required. Accordingly, the dry reagent test strips are simply contacted with a sample (e.g., a urine sample), and the results are read in as short as 5 minutes. In view of the following, it is clear that the implementation of the method can be carried out in a doctor's office, at a personnel place at a research or clinical workbench, or using a semi-automatic or fully automated device. The dry reagent test strips and methods of the present disclosure can be used at the point of care, thereby providing actionable results within a time frame, which has a positive impact on identifying the first effective antibacterial agent for the treatment of a patient that can be prescribed. The dry reagent test strips of the present disclosure have a simple colorimetric or other optical output, which should make it more directly integrated into the device, and allow flexible form options. The colorimetric output of the compounds and methods of the present disclosure can be read by a microplate reader, but can also be read by other spectrophotometric devices or even by device applications (e.g., mobile phone applications). The enhancement of the colorimetric signal can also allow accurate detection by the eye.

[0075] As illustrated below, the targeted small molecule probe disclosed in this article and PCT / US2020 / 048060 (incorporated by reference) is rapidly hydrolyzed by the targeted beta-lactamase studied herein. The results confirm that the compounds of the present disclosure have a significant preference for the ESBL subclass called CTX-M type beta-lactamase. For example, some compounds of the present disclosure are hydrolyzed by ESBL to release the trigger unit that activates the enzyme amplifier, start the amplification cascade event, and generate a colorimetric signal output indicating the presence of ESBL. ESBL detection compounds can be used as diagnostic reagents to detect pathogens that produce ESBL and guide patient care.

[0076] In various aspects, the present disclosure provides compounds and methods for detecting antibiotic resistance via identification of beta-lactamases and variants that are responsible for enzyme-mediated resistance mechanisms present in gram-negative and gram-positive bacteria. The targeted small molecule probes provided herein can be formulated into amplification assay compositions that can be used in the disclosed methods. Also provided is the use of compounds in the preparation of assay formulations for amplification methods.

[0077] The present disclosure provides a method for detecting the presence of one or more target β-lactamases in a sample by using a reagent test strip disclosed herein. In a specific embodiment, the method disclosed herein has the following steps: contacting the test pad of the dry reagent test strip disclosed herein with the sample, and then measuring the absorbance at a wavelength of 350nm to 950nm. The sample used in the method is usually obtained from a subject (including an animal subject), but the sample can also come from other sources, such as water samples, environmental samples, food samples, wastewater samples, etc. The sample obtained from the subject can come from various parts of the body. For example, the sample can be a blood sample, a urine sample, a cerebrospinal fluid sample, a saliva sample, a rectal sample, a urethral sample, or an eye sample. Regarding the latter three samples, these samples can be obtained by swabbing various areas. In a specific embodiment, the sample is a blood or urine sample. The subject from which the sample is obtained can be from any animal, including but not limited to humans, primates, cats, dogs, horses, birds, lizards, cattle, pigs, rabbits, rats, mice, sheep, goats, etc. In a specific embodiment, the sample is obtained from a human patient suffering from or suspected of having a bacterial infection. For example, a human patient may have or be suspected of having a urinary tract infection, sepsis, or other infection.

[0078] About the targeted β-lactamase, the dry reagent test strip of the present disclosure can be used to target each known β-lactamase class, including its subtype. For example, the compounds and methods disclosed herein can be used to depict and detect the presence of penicillinase, extended-spectrum β-lactamase (ESBL), inhibitor-resistant β-lactamase, AmpC type β-lactamase and carbapenemase. In particular, extended-spectrum β-lactamase or ESBL can be detected by the compounds and methods disclosed herein. For example, the compounds and methods disclosed herein can detect TEM β-lactamase, SHV β-lactamase, CTX-M β-lactamase, OXA β-lactamase, PER β-lactamase, VEB β-lactamase, GES β-lactamase, IBC β-lactamase. As shown in the research presented herein, various compounds disclosed herein can detect CTX-M β-lactamase with high specificity. The compounds and methods disclosed herein can also be used to detect various subtypes of carbapenemases, including but not limited to metallo-β-lactamases, KPC β-lactamases, Verona integron-encoded metallo-β-lactamases, oxacillinase, CMY β-lactamase, New Delhi metallo-β-lactamase, Serratia marcescens enzyme, imipenem hydrolyzing β-lactamase, NMC β-lactamase, and CcrA β-lactamase. For example, the studies presented herein demonstrate that various compounds of the present disclosure can detect CMY β-lactamase and KPC β-lactamase with high specificity. In a specific embodiment, the compounds disclosed herein can detect CTX-M β-lactamase, CMY β-lactamase, and KPC β-lactamase with high specificity. Further delineation of specific target β-lactamases in a sample can be determined by using β-lactamase inhibitors, as further described herein.

[0079] A chromophore generally refers to a colorless or light-colored chemical that an enzyme can convert into a dark-colored chemical that can be detected. In a specific embodiment, the chromogenic substrate is a substrate for a cysteine ​​protease, as further disclosed herein. Once subjected to the action of an enzyme (e.g., a cysteine ​​protease), the cleaved product can be quantified based on measuring absorbance at a wavelength, such as 350 nm, 375 nm, 380 nm, 385 nm, 395 nm, 400 nm, 405 nm, 410 nm, 415 nm, 420 nm, 425 nm, 430 nm, 435 nm, 440 nm, 445 nm, 450 nm, 455 nm, 460 nm, 465 nm, 470 nm, 475 nm, 480 nm, 485 nm, 490 nm, 495 nm, 500 nm, 505 nm, 510 nm, 515 nm, 520 nm 525nm, 530nm, 535nm, 540nm, 545nm, 550nm, 555nm, 560nm, 565nm, 570nm, 575nm, 580nm, 585nm, 590nm, 595nm, 600nm, 650nm, 700nm 750nm, 800nm, 850nm, 900nm, 950nm, or a range including or between any two of the foregoing absorbance values. For example, the cleavage product of Nα-benzoyl-L-arginine 4-nitroaniline hydrochloride (BAPA) can be quantified by measuring the absorbance at 405nm; the cleavage product of L-pyroglutamyl-L-phenylalanyl-L-leucine-p-nitroaniline (PFLNA) can be quantified by measuring the absorbance at 410nm; the cleavage product of azocasein can be quantified by measuring the absorbance at 440nm; the cleavage product of pyroglutamyl-L-phenylalanyl-L-leucine-p-nitroaniline can be quantified by measuring the absorbance at 410nm; the cleavage product of resorufin can be quantified by measuring the absorbance at 570nm; and the cleavage product of asymmetric azo-based chromophore can be quantified by measuring the absorbance at>520nm. Many devices can be used to measure light absorption, including microplate readers, spectrophotometers, scanners, etc. In some cases, the detection can be observed by the naked eye and appear as colored "stripes" or "dots" on a bar, etc. The light absorbance of the sample can be measured at various time points, such as 0 minutes, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, or a range including or between any two of the foregoing time points.For example, the light absorbance of the sample can be measured at 1 minute and 5 minutes, or at various time points therebetween, to determine the reaction rate.

[0080] Cysteine ​​proteases, also known as thiol proteases, are enzymes that degrade proteins. These proteases share a common catalytic mechanism that involves nucleophilic cysteine ​​thiols in a catalytic triad or dyad. Cysteine ​​proteases are commonly found in fruits, including papaya, pineapple, fig and kiwi. Caged or inactive cysteine ​​proteases refer to cysteine ​​proteases that can be activated by removing inhibitory segments or proteins. For example, caged / inactive papain includes papain-S-SCH3, which can remove inhibitory thiol segments by the cleavage of disulfide bonds. Examples of cysteine ​​proteases that can be used in the methods disclosed herein include, but are not limited to, papain, bromelain, cathepsin K, calpain, caspase-1, galactosidase, separase, adenovirus endopeptidase, pyroglutamyl peptidase I, sortase A, hepatitis C virus peptidase, Sindbis virus type nsP2 peptidase, dipeptidyl peptidase VI, deSI-1 peptidase, TEV protease, amidophosphoribosyltransferase precursor, γ-glutamyl hydrolase, hedgehog, and dmpA aminopeptidase. In a specific embodiment, a caged / inactive papain (e.g., papain-S-SCH3) is used in combination with a chromogenic substrate for papain (e.g., BAPA) in the methods disclosed herein. Caged / inactive cysteine ​​proteases can generally be reactivated by reaction with low molecular weight thiol anions (e.g., benzenethiolate anions) or inorganic sulfides. In a specific embodiment, the targeted small molecule probe of the present disclosure is a substrate for one or more targeted β-lactamases and releases a benzenethiol anion product: It then acts as a reaction amplifier by activating the caged / inactive cysteine ​​protease (eg, see Figure 1).

[0081] For the methods of the present disclosure, the absorbance of the sample can be compared with an experimentally determined threshold value to determine whether the targeted beta-lactamase is present in the sample. For example, if the sample absorbance value is greater than the experimentally determined threshold value, the sample contains the targeted beta-lactamase. Alternatively, if the sample absorbance value is less than the experimentally determined threshold value or control value, the sample is likely not to contain the targeted beta-lactamase. The method for generating the experimentally determined threshold value is taught in more detail in the embodiment section of this paper. In short, the experimentally determined threshold value can be determined by analyzing the receiver operating characteristic (ROC) curve generated from the bacterial isolate panel producing beta-lactamase, wherein one or more target beta-lactamases have a minimum limit of detection (LOD) in the isolate panel.

[0082] The manufacture of the dry reagent test strips of the present disclosure can be performed in various ways. For example, the reagent test components can be combined or individually contained in the solution phase in the reagent container, and then manually applied to the test pad of the dry reagent test strip. Alternatively, the reagent test components can be incorporated into an automated dispensing system, and the automated dispensing system then distributes the reagent test components to the test pad of the dry reagent test strip. The reagent test components are applied to the test pad of the dry reagent test strip and can be performed by freeze drying, imprinting, chemical or physical trapping, or being coated on the test pad.

[0083] In a specific embodiment, the manufacture of dry reagent test strips includes the preparation of coating solution. In one example, a mixture of a small molecule (targeted small molecule probe) and an indicator (L-BAPA) of the release of thiophenol in a low boiling point organic solvent such as methanol with a certain percentage of stabilizer / excipient (such as urea, sorbitol, trehalose, pullulan, polyethylene glycol, polyvinyl pyrrolidone, glycerol, sucrose, cellulose, dextran or gum arabic) is used to prepare a primary coating solution. In another example, a secondary coating solution is composed of a chemically modified papain in a buffer, and the buffer contains a certain percentage of stabilizer / excipient (such as urea, sorbitol, trehalose, pullulan, polyethylene glycol, polyvinyl pyrrolidone, glycerol, sucrose, cellulose, dextran or gum arabic). In this secondary coating solution, the buffer composition can be 20-100mM sodium phosphate or 20-100mM sodium citrate / citrate buffer. The buffer composition may contain a certain percentage of ionic or nonionic surfactants, which may include but are not limited to triton X-100, tween-20, etc. In one embodiment, a primary coating solution (10-50uL) is applied to a solid support. The solid support may be, but is not limited to, a member of a group selected from plastics, nitrocellulose, cellulose, glass fiber, Teslin, filter paper, etc. The plastic matrix may include but is not limited to high-density polyethylene (HDPE), low-density polyethylene (LDPE), polypropylene (PP), polyvinyl chloride (PVC), polycarbonate (PC), polysulfone (PSF), polystyrene (PS), Teflon (FEP) or Teflon (PFA). In one embodiment, the solid support coated with the primary coating solution is dried in a forced air oven at a temperature range of 30-80° C. for a period of time to obtain drying. In another example, the solid support is dried under ambient conditions. In one embodiment, a secondary coating solution is applied to a solid support containing a dried primary coating and subjected to a secondary drying period. A further method for manufacturing a dry reagent test strip is provided in the embodiment section herein. In some embodiments, the primary coating solution and the secondary coating solution are applied to discrete locations on the substrate. In other embodiments, the primary coating solution and the secondary coating solution are applied by laminating one another. In another embodiment, the coating solutions are applied at discrete locations so that, in use, one location containing the reagent contacts the sample before the second location, wherein the sample "wicks" along the substrate, contacting the contents of the two coating solutions / locations.

[0084] The disclosure also provides a test kit comprising one or more dry reagent test strips disclosed herein. The test kit may further comprise one or more additional containers, each of which has one or more desired materials (e.g., reagents, controls, and / or devices) from a commercial and user perspective. Non-limiting examples of such materials include, but are not limited to, needles, syringes, packaging, containers, vials, and / or tube labels listing contents and / or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.

[0085] The label can be located on or associated with the container. When the letters, numbers or other characters forming the label are attached, molded or etched into the container itself, the label can be located on the container; when the label is present in a vessel or carrier that also holds the container, the label can be associated with the container, such as as a package insert. The label can be used to indicate that the contents are to be used for specific therapeutic applications. The label can also indicate the instructions for use of the contents, such as in the methods described herein. These other therapeutic agents can be used, for example, in an amount indicated in a Physicians' Desk Reference (PDR) or as otherwise determined by a person of ordinary skill in the art.

[0086] The following examples are intended to illustrate, but not to limit, the present disclosure. Although they are typical of those procedures that might be used, other procedures known to those skilled in the art may alternatively be used.

[0087] Example

[0088] Identification of CTX-M-type enzyme predominance in a Californian cUTI patient population. Ceftriaxone nonsusceptibility (minimum inhibitory concentration [MIC] ≥ 2 μg / mL) was used as a surrogate screen for ESBL-producing uropathogens. Concurrently, the microbiology team performed a whole-genome sequencing study that determined that ceftriaxone-resistant uropathogens predominantly harbored CTX-M-type ESBL enzymes (identified in 91% of the isolate collection) and were the primary cause of the spread of this phenotype in the cUTI patient population within California, with the CTX-M-15 variant (56% of the isolate collection) being the most common CTX-M-type enzyme identified.

[0089] Develop highly specific ESBL targeted probes to specifically and rapidly detect CTX-M type enzymes using a paper-based strip format. Since CTX-M type enzymes predominate in patients with cUTI, ESBL targeted probes that specifically detect CTX-M-15 and other common CTX-M type variants were focused on. The first ESBL targeted probe that specifically detects CTX-M type was identified. This ESBL targeted probe (7R)-8-oxo-7-(2-phenylacetamido)-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (Sub-1) was used as an internal reference standard in establishing acceptable detection limit thresholds and targeted probe performance in clinical urine samples. Although the performance metrics of Sub-1 are sufficient for clinical use, the stability and promiscuity characteristics of Sub-1 are not sufficient for rapid detection of ceftriaxone non-susceptibility directly from urine.

[0090] ESBL-targeted probes with at least the following favorable criteria were evaluated for use in rapid diagnostic tests:

[0091] 1. Aqueous stability - measured by non-selective hydrolysis

[0092] a. Favorable standard: k(hydro)<0.0062mM / min

[0093] 2. Activity of CTX-M-15 against target β-lactamase – measured using recombinant β-lactamase

[0094] a. Favorable standard: k(β-lactamase)>0.0568mM / min

[0095] 3. Activity against off-target lower generation β-lactamases (with priority given to the most common TEM-1b)

[0096] a. Favorable standard: k(TEM-1b)<0.02135mM / min

[0097] ESBL targeting probes showing the above favorable criteria were further investigated to determine the kinetic parameters and the preference of CTX-M-15 (target) over TEM-1b (off-target) to minimize the possibility of false positive detection. ESBL targeting probes with a 10-fold improvement in specificity over TEM-1b (common off-target enzyme) for CTX-M-15 (common target enzyme) were confirmed to be strong candidates for further testing by a comprehensive panel of 96 bacterial isolates to determine the ability of each targeting probe to distinguish target and off-target β-lactamases. Further, ESBL targeting probes were evaluated using a paper-based strip format.

[0098] 5 probe hit pools are evaluated using 96 bacterial isolate panels. In these studies, 96 bacterial isolate panels consist of 47 cefotaxime (CTX) sensitive and 49 CTX non-sensitive Gram-negative bacteria (GNB). As described above, CTX is a substitute for detecting ceftriaxone sensitivity, and therefore, as a reference phenotype, it is applied to true positive, CTX non-sensitive (including CTX resistance and intermediates) and true negative, CTX sensitive grouping. Prepare whole cell suspensions to produce 2.5X 10 6 The experimental concentration of CFU / mL was 1.5 ng / mL. In a 96-well plate, wells were prepared with all DETECT reagents except the targeted probe under investigation. The bacterial suspension was transferred to the prepared wells and the given probes (Sub-1, (7R)-7-(2-(1H-tetrazol-1-yl)acetamido)-8-oxo-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-5835), (7R)-7-(3-methylisoxazole-5-carboxamido)-8-oxo-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-1468), (7R)-8-oxo-3-((phenylthio)methyl)-7-(2-(pyrrolidone)-1-yl)acetamido)-8-oxo-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-1468), After adding stock solutions of (7R)-8-oxo-3-((phenylthio)methyl)-7-((S)-piperidine-3-carboxamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-3462), (7R)-8-oxo-7-(2-phenoxyacetamido)-3-((phenylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (BAD-7465)), the initial time point (0 min) was recorded. The absorbance of the wells at 405 nm was collected at 0 and 30 min using a simple benchtop plate reader. A "DETECT score" value was then calculated for each sample by subtracting the 405 nm absorbance recorded at the 0 minute time point from the 30 minute time point. Thus, each sample was identified as having a unique DETECT score, which could then be separated into positive and negative phenotypic subgroups via ROC curve analysis to determine the threshold.

[0099] The criteria used to define two lead probes from the five hits included (1) general stability as a measure of the rate of non-selective hydrolysis of a given probe (the lower the k(hydro), the more stable the probe); (2) a plot of "true positives" (TP) versus "true negatives" (TN) detected by each probe, and (3) overall accuracy as defined by application of a standard receiver operating characteristic (ROC) curve.

[0100] A summary of the results of these studies is listed in Table 2. Targeted probes BAD-5835 (G2B) and BAD-5627 were identified as strong lead candidates due to their stability, high sensitivity, and specificity.

[0101]

[0102] BAD-5835 and BAD-5627 ESBL-targeted probes were evaluated using a fully characterized test set of uropathogen isolates. BAD-5835 and BAD-5627 were evaluated using a fully characterized test set of uropathogen isolates, which contained uropathogens collected in 2019 at San Francisco (SF) General Hospital in SF, CA (n=650). These isolates have been phenotypically characterized and are currently being analyzed by whole genome sequencing (with Illumina TM The test set was selected because uropathogens were cultured from urine samples sent to a central laboratory in a public hospital for suspected urinary tract infection (UTI). Therefore, it represents the patient population evaluated with the rapid diagnostic solid phase test strip test format disclosed herein (e.g., U-detect). Patient data will not be known, and only biological information will be provided to establish test performance indicators using BAD-5835 or BAD-5627 in the rapid diagnostic solid phase test strip test format (e.g., U-detect) of the present disclosure.

[0103] Shorten the result time of chemical-driven detection systems to produce results in less than five minutes to achieve target product profiles. In order to allow immediate guidance on antibiotic prescribing, the acceleration of the result time dynamics was evaluated. Currently, there is no rapid diagnosis on the market that can guide the initial antibiotic therapy selection for the treatment of complicated urinary tract infections (cUTI). Bacterial culture and antibiotic sensitivity testing (AST) are the current gold standards, however, its TTR may take up to 3 days. The solution based on DETECT (i.e., DETECT 1.0) TTR is currently 30 minutes, including the determination of incubation time, to directly derive antibiotic sensitivity results from urine samples from patients. It has become apparent that the ideal target product profile (TPP) for rapid diagnosis includes a TTR with a 5-minute time frame. The product form is a urine immersion test (i.e., a dry reagent strip test), which is part of the current diagnostic workflow for cUTI treatment. The TTR of the urine immersion test is five minutes, which makes it very effective in the diagnostic workflow because it immediately provides results that can support the selection of appropriate antibiotic therapy. Beyond that, it is part of the clinician’s workflow, which lowers the barrier to implementation into the hospital setting. Therefore, in order for U-detect to be clinically effective, it is important that it meets the 5-minute TTR of the current urine dip test. Therefore, in order to achieve a truly rapid and clinically effective TTR of 5 minutes or less, the signaling layer of DETECT 1.0 needs to be improved.

[0104] DETECT 1.0 consists of two layers: targeting and signaling. The signaling layer of DETECT is responsible for providing signal output when the chromogenic BAPA is hydrolyzed by papain. The rate of signal output through the DETECT 1.0 system depends on the rate of hydrolysis of BAPA by papain. Therefore, in order to achieve optimal TTR for U-detect of five minutes or less, the kinetic rate of BAPA hydrolysis needs to be increased. To achieve this, the current compound BAPA will be modified to create a BAPA with improved hydrolysis rate (k cat , k cat / K m ) of BAPA derivatives, the improved hydrolysis rate will translate into faster signal output and thus reduced TTR. Modified BAPA derivatives containing a highly conserved hexapeptide sequence (X-QVVAGA-Y, X and Y = quencher and dye) were investigated, which demonstrated remarkable substrate specificity (kcat / Km 2.9x10 at 30°C). 9 M -1 min -1), but with the disadvantage of solubility issues. In order to improve the solubility of the peptide, the peptide was modified to incorporate hydrophilic amino acid residues. For the resulting BAPA derivatives, the improved hydrolysis rate was examined at ambient temperature.

[0105] The feasibility of improving the time to result (TTR) of DETECT was determined by examining improved BAPA hydrolysis rates. The BAPA (Bz-R-pNA) substrate utilizes an arginine (R) residue to direct moderate recognition by papain. However, since it has been determined that papain utilizes hydrophobic residues, BAPA derivatives incorporating phenylalanine residues (F) and glutamine residues (Q) were first evaluated, designated Bz-FR and Bz-QFR substrates, respectively. Both peptides contain the N-terminal benzoyl (Bz) of BAPA and the C-terminal chromogenic p-nitroaniline (pNA). The hydrolysis rates of Bz-FR and Bz-QFR substrates were compared to BAPA using DETECT 1.0. In addition, the ability of the tripeptide and dipeptide substrates to provide a significant absorbance change (DETECT score) and maintain a high signal-to-noise ratio (S / N) at 5 minutes was also examined (Figure 11). The introduction of the Phe residue provided a significant increase in hydrolysis relative to BAPA, with a binding affinity (K m ) by a factor of ~7 and turnover number (k cat ), which resulted in an 88-fold increase in substrate specificity (k cat / K m ) as shown in Figure 11A. Similarly, the tripeptide Bz-QFR incorporating a Gln residue does not appear to be as active as the Bz-FR substrate, but provides a modest improvement over BAPA. Overall, both substituted BAPA derivatives provide an improvement in absorbance change (defined as DETECT score) (see Figure 11B) and an increase in S / N (see Figure 11C) after papain activation. In addition, the papain used in this assay is at least 60 times less than the papain used by BAPA (DETECT 1.0).

[0106] Improved time to result (TTR) was demonstrated with an alternative papain substrate, Bz-FR, in clinical isolates. Since the Bz-FR substrate had an excellent hydrolysis rate and maintained a high S / N in papain activation studies, Bz-FR was subsequently examined for its ability to produce optimal signal output within 5 minutes with clinical bacterial isolates. This study utilized an ESBL-targeted probe (BAD-5835) to detect cefotaxime conjugated to the Bz-FR papain substrate to produce a signal output. Clinical isolates CTX-M-15 (SF674), SHV-12 (CDC-12), CMY-2 (SF207), KPC-2 (B2), and TEM-20 (CDC-58), which are resistant to cefotaxime and produce β-lactamases (herein considered "positive" isolates), were examined against "negative" isolates (SF334 and SF505), which are susceptible to cefotaxime. In 10 sera for each isolate, 10 sera were added to the sera for 10 sera. 6 CFU / mL standard concentration, for DETECT 1.0 and DETECT with Bz-FR, DETECT score was checked after 5 minutes of assay incubation. In addition, the S / N between each assay condition was checked to evaluate how the signal from the 'positive' resistant isolate was compared with the signal generated by the 'negative' isolate. For DETECT 1.0, the signal generated at 5 minutes was difficult to distinguish between positive isolates and negative isolates, where the signal generated by SF674 and B2 was greater than that of negative isolates (high ~ 3 times) (see Figure 12A). For DETECT containing Bz-FR, there was a much higher absorbance change after 5 minutes across positive isolates and negative isolates, but when comparing positive (SF674) and negative (SF505) isolates, there was only a ~ 2-fold signal increase (see Figure 12B). However, for BZ-FR, the DETECT signals generated by all positive isolates were greater than the negative control, ranging from up to 1.9 times the average signal of the negative control. In addition, for Bz-FR, there was a -50% signal increase for the positive (SF674) compared to the negative (SF5050) (see Figure 12C). Continuing to improve the level of background signal generated by negative isolates (or true negative samples) can be used to have a reliable test that can distinguish true positive samples (antibiotic resistant) from true negative samples (antibiotic sensitive). The way to minimize the background signal generated with Bz-FR in negative isolates needs further improvement.

[0107] The focus of this goal is to identify signaling substrates for papain that can maintain high levels of signal in true positives (cefotaxime resistant) while reducing the amount of signal generated in negative isolates (cefotaxime sensitive). This is achieved by examining derivatives of the Bz-FR substrate by incrementally changing the scaffold as follows: first, replacing the recognition residue at the 2nd position, such as the (F) residue, with an alternative hydrophobic residue to suppress background noise that can be generated in the isolate. Secondly, the (F) and (R) positions are exchanged to evaluate whether overreactivity can be suppressed. Each Bz-FR derivative undergoes a rigorous evaluation using a validation process, in which certain criteria must be met to ensure that the best candidates can be identified and used in goal 2 and ultimately in a test format. In view of this, four BAPA derivatives were evaluated, which included replacing the Phe residue with Val and Trp, and replacing the Arg residue with Lys, respectively, and Arg and Phe were exchanged with each other. BAPA derivatives were tested using an activity assay that used cysteine ​​for papain activation to determine kinetic parameters, and established a papain / BAPA derivative ratio to maximize S / N. Those BAPA derivatives with S / N>3 and DETECT scores>0.25 were to be used for further optimization using recombinant target biomarkers CTX-M-15 and targeted probe BAD-5835, with a 5-minute assay incubation time. The optimal ratio of papain / BAPA derivatives can thus be identified, and the noise level generated by BAD-5835 from spontaneous hydrolysis can be determined.

[0108] The BAPA derivatives that pass the biochemical testing stage will be subjected to microbiological testing using clinical isolates (stages 3-7). In stage 3, the ability of each BAPA derivative to escape hydrolysis by bacterial proteases or amidases is checked. If there is no indication of nonspecific hydrolysis of the BAPA derivative, then in stage 4, it is tested for its ability to produce a viable signal about a positive isolate in 5 minutes or less, and the positive isolate contains a beta-lactamase target biomarker that can be distinguished from a negative isolate. For BAPA derivatives to be considered for further testing, it should confirm a DETECT score of 0.25 or higher for the positive control isolate, and for the negative control isolate (SF505), confirm that the DETECT score is <0.15. If the signal output level is reached, then in stage 5, a higher resolution of the ratio of BAPA derivatives / papain is performed by using the optimization of the chessboard assay to maximize the signal output, and the BAPA derivative is further optimized. With the significant improvement in signal output, a limit of detection (LOD) study was conducted using a panel of 7 clinical isolates to confirm that the signal output was less than 10 5The LOD of CFU / mL. Finally, the BAPA derivative optimized with the targeted probe BAD-5835 was tested against a panel of 96 bacterial isolates, which consisted of 47 cefotaxime-sensitive and 49 cefotaxime-resistant Gram-negative bacteria. DETECT scores were calculated for each isolate sample and grouped into positive and negative phenotypic subgroups to establish a threshold. Clinical isolates that generate a DETECT score greater than the threshold are considered positive, and the sensitivity and specificity of DETECT containing BAPA derivatives are determined by analyzing the DETECT signal via a receiver operating characteristic (ROC) curve analysis. Ideally, the BAPA derivative will generate 90% sensitivity and 92% specificity within 5 minutes for U-DETECT determination.

[0109] The signal output of the chemically driven detection system is adjusted from 405nm to 525nm for universal compatibility with urine analyzer systems. Although it would be advantageous to have fast TTR, maximizing sensitivity and adjusting the signal wavelength of DETECT 1.0 would allow for better positioning of the technology for multiple applications such as instant detection, visual detection, and multiplexing. The improvement of DETECT technology also ensures compatibility of the test with existing urine analyzers. As a dry reagent test strip (U-DETECT) that can be installed on an existing urine analyzer, the optical specifications of U-DETECT (particularly the wavelength of the signal output) must be compatible with existing analyzers on the market to reduce the barriers to adopting the test. The replacement of the current signal conduction output portion (p-nitroaniline) is a key step in matching the signal conduction wavelength with those on the urine analyzer system, such as the iChemVelocity of Beckman Coulter and the CLINITEK Novus of Siemen, which have the largest market share.

[0110] The signal output of DETECT 1.0 is currently read at 405nm, and through modification of the signaling output molecule, longer wavelengths (525nm or greater) can be obtained, accompanied by improved photophysical properties, allowing sensitive detection of ceftriaxone resistance. In the signaling layer of DETECT 1.0, upon triggering the signaling cascade from the presence of the ESBL target biomarker, BAPA is hydrolyzed by papain to release the chromogenic p-nitroaniline. This chromogenic moiety has been widely used in substrates for proteolytic enzymes, but has several disadvantages that allow its consideration in diagnostics. p-Nitroaniline is a relatively poor chromophore, with an absorbance wavelength of 9,767M-1cm at its absorbance wavelength of 405nm. -1 Since the absorption intensity is proportional to the extinction coefficient, the absorption intensity of the sample with >25,000 M -1 cm-1 It would be suitable to replace the p-nitroaniline chromophore with a chromophore with an extinction coefficient of 0.1 and an absorbance wavelength of >525 nm. One possible candidate is the fluorescent indicator, resorufin, which has an extinction coefficient of 56,000 M at its absorbance wavelength of 570 nm. -1 cm -1 In addition, it has a relatively low pka (OH group), high water solubility (1 mg / mL) and high fluorescence quantum yield (Φ=0.74 in water). Due to the high extinction coefficient of resorufin, the color change from light yellow (quenched form) to bright pink (unquenched) can be observed by the naked eye. A notable application of resorufin is as a chromogenic probe for the detection of anionic sulfite (SO3 2- ), which has been demonstrated by Choi et al. Resorufin is quenched ("turned off") by the addition of a protecting group that is susceptible to cleavage by sulfite. Once the protected resorufin encounters sulfite, the protecting group will be cleaved to produce a chromogenic resorufin with a 320-fold response in absorbance change (see Fig.13 In addition, the chromogenic probe serves a dual role as a fluorescent molecule, and its structural changes can be monitored by fluorescence, with the sulfite probe providing a 57-fold increase in fluorescence, with a peak fluorescence of 4.9 x 10 -5 Therefore, resorufin is a viable candidate for investigation as a next generation signaling output for DETECT to allow testing with existing urine analyzers.

[0111] The chromogenic p-nitroaniline was replaced with a commercial chromophore to improve sensitivity and increase the absorbance wavelength to >525 nm. Using the current candidate Bz-FR-pNA, the p-nitroaniline (pNA) chromophore was replaced by resorufin (Res) to produce the Bz-FR-Res signaling output molecule (see Figure 14A). In addition, BAPA derivatives were also studied with the resorufin chromophore (see Figure 14B). The generated BAPA-Res derivatives (dBAPA-Res) were subjected to rigorous biochemical and microbiological validation using the above methods. A rapid validation process was applied to identify dBAPA-Res candidates that had improved hydrolysis rates to produce signaling outputs in 5 minutes or less, improved sensitivity to target biomarkers, and longer absorbance wavelengths (>525 nm) for compatibility with existing urine analyzers (see Figure 14B).

[0112] The chromogenic moiety for DETECT was synthesized and developed to improve sensitivity and increase the absorbance wavelength to greater than 525 nm. Given the ease of synthesis and chemical adjustment of azo dyes (which absorb in the wavelength range of 400 nm and up to 600 nm, with up to 50,000 M -1 cm -1 Inspired by the photophysical properties of azo-based chromophores, azo-based chromophore moieties for DETECT will be developed that have improved sensitivity (over DETECT 1.0 with BAPA) and are compatible with existing urine analyzers.

[0113] Synthesis and development of novel chromogenic dBAPA-Azo derivatives. A novel chromophore with an absorbance wavelength greater than 525 nm will be identified. This is achieved by synthesizing an asymmetric azo-based chromophore that is incorporated into a benzothiazole moiety connected to an aniline group via a diazo functionality (see Figure 15A). Benzothiazole acts as an electron withdrawing group from aniline to promote the intramolecular charge transfer (ICT) process. The chromophore will be obtained by a diazo two-step coupling reaction. Benzothiazole amine (1) undergoes diazo formation to obtain an intermediate (2). Then, the molecule (2) undergoes electrophilic aromatic substitution with an aniline derivative (3) to provide the desired chromophore (4). In order to ensure that a chromophore with superior properties exceeding p-nitroaniline is identified, twelve azo-based derivatives with different functionalities are evaluated. There are 4 representative scaffolds (X = CN, NO2, Br, Cl), which are composed of functionalities that promote the ICT mechanism for longer wavelengths and high extinction coefficients. Within each of these scaffolds, various R groups (H, OCH3 or SO3) are examined for improved photophysical (wavelength and extinction coefficient) and physical (solubility) properties. Due to the hydrophobicity of these chromophores, the photophysical properties will first be evaluated in organic solvents such as dichloromethane, methanol and acetonitrile. This allows the characterization of chromophores with different polarities and the evaluation of how the absorbance changes under these conditions. Next, the solubility and buffer conditions in water in which DETECT is run are evaluated to monitor the absorbance with respect to concentration. Finally, the absorbance under acidic (pH 4), neutral (pH 7) and alkaline (pH 9) conditions will be examined to determine that pH does not have a negative effect on absorbance (i.e., a decrease in acidic or neutral). Wavelengths greater than 525nm are shown, accompanied by greater than 25,000M -1 cm -1 Chromophore derivatives with an extinction coefficient of 0.040 and water (and / or buffer) solubility in the range of 0.25-0.5 mg / mL were considered as leads for performing C-terminal modifications of each peptide backbone identified.

[0114] The indoleaniline chromophore moiety used in DETECT was synthesized to improve sensitivity and increase the absorption wavelength to >525 nm. Indoleaniline chromophores are derived from aniline and phenolic compounds, which in the presence of an oxidizing agent will provide an indoleaniline product. Indoleaniline chromophores have been widely used in the permanent hair coloring industry, with patents on chromophore components dating back to as early as the 1880s. The tunability of these chromophores has enabled chemists to develop a variety of colors with different physical and photophysical properties, with absorption wavelengths ranging from 500 and up to 700 nm, with greater than 25,000 nm. -1 cm -1 Due to their ease of synthesis and tunability, these classes of chromogenic dyes are well suited for incorporation into the signaling layer of DETECT to improve sensitivity and increase the signaling wavelength (see FIG16A ).

[0115] Synthesis and development of chromogenic indole aniline derivatives to produce dBAPA-Indo papain substrates. Nine indole aniline derivatives will be studied to determine candidates with absorbance wavelengths greater than 525nm. The scope of work consists of synthesis and structural characterization, as well as physical and photophysical characterizations such as solubility and absorbance measurements under different conditions. Finally, coupling efficiency studies will be conducted to ensure that there is a certain level of reactivity for conjugation to the peptidyl papain substrate. After identifying the leading chromogenic indole aniline derivatives, this component will be modified on the C-terminus (see Figure 16B).

[0116] The chromogenic dBAPA derivatives are validated to demonstrate improved sensitivity and increased absorbance wavelength for interpretation by existing analyzers. Although the backbones of the papain substrates (Bz-XX and Bz-FR) have been validated to demonstrate improved TTR, the chromogenic substrates will be subjected to a validation process to maintain the hydrolysis rate for fast TTR and demonstrate improved sensitivity for detecting target biomarkers. Biochemical validation of dBAPA-Res, dBAPAAAzo, dBAPA-Indo derivatives will be performed using a papain activation assay. In the papain activation assay (Phase 1), the evaluation of the maintenance of S / N and absorbance change (DETECT score) in 5 minutes or less relative to the lead p-nitroaniline-containing substrates (Bz-XX-pNA and Bz-FR-pNA) will be determined. In addition, the catalytic efficiency will be investigated to ensure that the hydrolysis rate is not significantly affected by the introduction of each chromophore derivative and that the kcat / Km is maintained at 10 5 -10 6 M -1 min -1 The three best candidates that can maintain (or improve) hydrolysis rate, S / N, and DETECT score in 5 minutes or less will be identified.

[0117] Microbiological validation of dBAPA-Res, dBAPA-Azo, and dBAPA-Indo derivatives was performed against a panel of clinical E. coli isolates. This panel consisted of 7 isolates obtained from patient blood or urine samples and showing varying susceptibility to cefotaxime. In Phase 2, each BAPA chromophore derivative was examined for its ability to escape hydrolysis by bacterial proteases or amidases and to ensure that the introduction of the chromophore did not promote nonspecific hydrolysis. In Phase 3, an LOD study using a panel of clinical isolates was performed to confirm that the chromophores were resistant to cefotaxime in <10 isolates. 5 The detection limit of CFU / mL improvement is improved, and it is ensured that there is no significant signal from true negative isolates (sensitive to the effect of cefotaxime). When necessary, the optimization of BAPA derivative / papain ratio can be carried out (stage 4) to maximize the signal output. This point is only considered when significant noise is generated by the nonspecific hydrolysis of the targeted probe (BAD-5835). Finally, in stage 5, a validation study using 96 isolate experimental panels is carried out to ensure that sensitivity and specificity are maintained relative to DETECT 1.0. DETECT scores greater than the threshold are regarded as positive, and the sensitivity and specificity of the modified assay are determined by analyzing the DETECT signal via receiver operating characteristic (ROC) curve analysis. The chromogenic BAPA derivative that can produce at least 90% sensitivity and 92% specificity in less than 5 minutes is identified as a leading chromogenic substrate for papain, which will be used for the further development of U-DETECT.

[0118] The feasibility of converting the assay components to a strip format was investigated by demonstrating that the activity of the components was retained (relative to the assay) by cysteine ​​activation. Initial feasibility studies on dry reagent test strips will focus on the following five criteria:

[0119] (1) Solid phase material evaluation, compared to saturated sample volume (resistance to drying out within 30 minutes), to identify appropriate test strip configuration to retain moisture over time.

[0120] (2) Studies on the successful drying of solid materials: cellulose and glass fibers (drying time and temperature).

[0121] (3) Evaluation of the assay read time for solid phase material / each sample type (dosed on paper and dried on paper) (20 minutes).

[0122] (4) Very small formulations optimized to enhance the signal produced on selected membranes.

[0123] (5) Sample type comparison: Spiked aqueous samples (cysteine ​​solution, 10 μL) were compared to the assay format (evaluation at 405 nm).

[0124] Overview of the manufacturing process: Using grade 222 filter paper as the solid substrate (reagent pad), the DETECT assay components were coated in two steps. The first step consisted of coating the reagent pad with the methanol soluble components (BAPA and BAD-5835) and drying in a forced air oven set at 37°C. The second coating consisted of adding the water soluble components (buffer salts and papain) and secondary drying in an oven at 37°C. The reagent pad was then adhered to polyester film and then cut into 5 x 5 mm reagent strips for testing (see Figure 7 ). Multiple formulation combinations of DETECT components were examined to determine the optimal change in reflectance over time.

[0125] Test Strip Fabrication: An overview of the fabrication process from liquid to solid phase testing is shown in Figure 6. The fabrication process is performed by cutting a piece of the selected reagent pad (Ahlstrom- Grade 222 filter paper). For the first coating step, the solution of the methanol soluble components (BAPA and BAD-5835) was transferred to a weigh boat and the filter paper was completely immersed to ensure complete saturation. Any excess solution was removed with a glass rod and placed in a forced air oven and dried at 37°C for 45 minutes. The secondary coating was performed by preparing the water-soluble components (10mM sodium phosphate buffer, 25mM Bis-tris, 1.125mM EDTA, 12.5mM NaCl and papain at 0.6mg / mL) and transferring the solution to a weigh boat in which the dry filter paper could be completely immersed to ensure saturation. Excess solution was removed with a glass rod and the paper was placed in an oven and dried at 37°C for 60 minutes. In a dry room (relative humidity <20%), the dry filter paper was adhered to a polyester film support. Using 3M 415 double-sided film tape, the dry filter paper was adhered to a piece of Tekra 10mil 339 opaque white polyester film, and apply slight pressure to ensure that filter paper has adhered with hand pressure roller.Then the filter paper adhered to the film is cut into 5mm wide strips, to provide test strips (Fig. 1) with 5x 5mm reagent pad. The order of using DETECT components generally includes first adding methanol soluble components, followed by water soluble components. Having methanol as a secondary coating step may be harmful to papain. In addition, determine that the sample volume of at least 20 μ L effectively prevents the drying out of the reagent pad during the incubation time of 20 minutes.

[0126] Dry reagent test strips are used to detect the feasibility of antibiotic resistant bacteria. The papain activity activated by cysteine ​​is evaluated by using two test strips, wherein one of the test strips receives 100 μM cysteine ​​(sample), and the other test strip receives buffer (control). For each strip, the reflectivity is monitored by the percentage reflectivity (minus control) over time.

[0127] Study 1 Materials: Papain, BAPA, BAD-5835, and cysteine ​​(100 μM).

[0128] Study 2 Materials: papain, BAPA, BAD-5835, and CTX-M-15 (1 nM or 4 nM).

[0129] To confirm that the DETECT components support the manufacturing process, two separate studies were conducted, in which papain activity was evaluated by cysteine ​​activation in Study 1, and β-lactamase targeted probes were evaluated by CTX-M-15 activation in Study 2. In Study 1, different formulations (i.e., different amounts of papain and BAPA) were used to prepare test strips to obtain the highest possible reflectance change when a yellow signal was generated by activating papain (see Figure 8), and were measured with a Konica Minolta reflectance spectrophotometer. With formulation 1 as the baseline concentration, 0.6 mg / mL (1X) papain, 2.56 mg / mL (1X) BAPA, and 1.28 mg / mL (1X) BAD-5835 were used. Any formulation used thereafter was an increase in all components or only an increase in the amount of papain and BAPA.

[0130] Study 1. Prepare single reagent pad test strip, to study how to best solve the reflectivity after activation signal cascade and signal conduction optimization. Initially, four unique preparations (1-4) were used, wherein papain or all components simultaneously increased relative to preparation 1 (1X). For each preparation, the ability of papain activated by cysteine ​​was checked. For each preparation, two test strips were specifically used for experimental operation, wherein one of the test strips received 20 μL 100 μM cysteine ​​(sample), and another test strip received 20 μL sodium phosphate buffer (control), and the percentage reflectivity was recorded every 4 minutes (using 405nm wavelength), until the incubation time of 20 minutes at ambient temperature was passed (see Fig. 8). In the absence of color, most of the light is reflected, and in the presence of color, a significant amount of light is absorbed, and the amount of light reflected is reduced. Therefore, as the color signal is generated by the DETECT system, the percentage reflectivity can be reduced over time. The difference in percent reflectance (%R score) between the sample and control was determined by subtracting the percent reflectance of the control strip from the sample strip for each time point to generate a %R score that increased over time (see Figures 9A-B). Similarly, the change in reflectance over time was determined to generate a DETECT %R score (%R score). 20分钟 -% R-Rating 2分钟 ) to determine which formulation observed the greatest change after 20 minutes of incubation time.

[0131] Studies 1.1 and 1.2 used unique formulations to evaluate the DETECT component on the test strips by cysteine ​​activation of papain. In Study 1.1, DETECT%R scores as high as 7.70 and 7.73 were observed for formulations 2 and 4, respectively. Given that formulation 4 used a higher amount of the BAD-5835 targeting probe and was generally a contributor to noise (at least in the assay format), formulation 2 was the focus for optimizing conditions, where the amounts of papain and BAPA were increased while keeping the BAD probe unchanged.

[0132] Study 1.2, with respect to the %R score increase of papain activation by cysteine ​​reaching the maximum, examined up to four times of preparation 1 (for papain and BAPA). Increasing the amount of papain and BAPA can provide the %R score improved relative to preparation 2 as shown in Figure 9D, wherein preparations 7 and 9 provide similar responses over time. In addition, preparations 7 and 9 provide similar improvements based on DETECT %R score, which is the highest value observed in these feasibility studies so far. This is an example in which papain activation by cysteine ​​has been confirmed in a test strip format. This example shows that the DETECT component can be converted into a test strip format.

[0133] Results of Study 1. Papain was able to support the manufacturing process and retain its enzymatic activity, as demonstrated by cysteine ​​activation. The BAD-5835 targeting probe was not degraded by the manufacturing process, if it had been degraded, the control strip would have shown a significant change in reflectivity. Increasing the amount of papain in the test strip gave an overall increase in %R score and DETECT %R score.

[0134] Study 2. Formulations 7-9 were used to evaluate the activation of the DETECT component on the test strip by CTX-M-15. Given that formulations 7-9 gave the highest reflectance changes (%R scores and DETECT %R scores) in the cysteine ​​activation study, these three formulations were used to evaluate the ability of the BAD-5835 β-lactamase small molecule targeted probe to detect the presence of recombinant CTX-M-15. If the small molecule targeted probe is not severely affected by the manufacturing process, it will be hydrolyzed in the presence of CTX-M-15 and release the trigger unit to initiate the signaling cascade, thus providing a yellow colorimetric response. For this study, 1 nM or 4 nM of CTX-M-15 was selected because these concentrations are above the dynamic range and will undoubtedly activate the DETECT system if the targeted probe has not undergone any modifications during the manufacturing process. For each preparation, two test strips were specifically used for the experimental run, one of which received 20 μL 1nM or 4nM CTX-M-15 (sample), while the other received 20 μL sodium phosphate buffer (control), and the percentage reflectance (using 405nm wavelength) was recorded every 4 minutes until 20 minutes of incubation time had passed at ambient temperature. % reflectance score (%R score) and DETECT%R score (see Figure 10A-B) were calculated for each preparation, and preparation 9 obtained a %R score of ~13, which was surprisingly similar to the response observed in the cysteine ​​activation in Study 1.2. Based on the DETECT%R score, each preparation provided a moderate response in the presence of CTX-M-15, and there was a slight difference between using more BAPA (preparation 9) or less BAPA (preparation 7). The factor that affects the change in reflectance to the maximum is still the amount of papain used to make the test strips. These results indicate that the DETECT component in a test strip format can detect the β-lactamase target biomarker CTX-M-15, and there is no indication that the targeting probe was affected by the manufacturing process. This shows that the amplification system of DETECT in a test strip format is able to detect the presence of the β-lactamase CTX-M-15.

[0135] Highlights from Study 1 and Study 2:

[0136] (1) The β-lactamase targeting probe (BAD-5835) retained its ability to detect the presence of CTX-M-15.

[0137] (2) Addition (2X→4X) of BAPA provided a modest increase in the change in percent reflectance (%R score and DETECT %R score).

[0138] (3) Determine the order of coating reagents on the reagent pad filter paper to provide a working test strip for future studies (detection limit, stability, material selection, etc.).

[0139] (4) Reagent pad in this feasibility study - Ahlstrom - Grade 222 filter paper.

[0140] (5) The drying temperature used (37 °C) can be optimized to have a scalable manufacturing process.

[0141] (6) It was determined that at least 20 μL was a useful amount of sample volume required to prevent drying during the incubation time.

[0142] (7) Papain activity was retained by demonstrating its activation by cysteine ​​(Studies 1.1 and 1.2). The targeted probe retained its ability to detect the presence of recombinant CTX-M-15 β-lactamase (Study 2).

[0143] The feasibility results of converting the assay components to a strip format were demonstrated by demonstrating that the activity of the components was retained (relative to the assay) by cysteine ​​activation. The components could be successfully dried on test strips and demonstrated comparable activity levels (by cysteine ​​activation) to other assay formats (20 minutes, ≤15% difference in activity). Additionally, the BAD-5835 (G2B) β-lactam substrate did not show any signs of degradation, which could lead to false positive activation of the system during manufacturing.

[0144] It is found that papain is not affected by the manufacturing process. In addition, the control strip does not show any significant reflectivity change, which is caused by the papain activation of the trigger unit released, and the trigger unit is released by the degradation of the small molecule targeted probe (see Figure 8 A). Similarly, for research 2, two test strips are used to check the ability of recombinant β-lactamase (CTX-M-15) to hydrolyze small molecule targeted probe (BAD-5835) and trigger amplification cascade. The sample test strip accepts 1 or 4nM β-lactamase, and the control accepts buffer, and the reflectivity is monitored for a total of 20 minutes every 4 minutes (see Figure 8 B). There is a significant change in reflectivity, which indicates that the targeted probe is feasible and can be recognized by β-lactamase. Although the moderate resolution between the two concentrations is observed, this is expected in view of the fact that the two concentrations are much higher than the dynamic range of the CTX-M-15 target biomarker.

[0145] Improvement of the manufacturing process of dry reagent test strips. In view of the fact that it is feasible to transform the DETECT component into the dry reagent test strip form, there is a significant improvement space about other parameters such as drying temperature, which will affect the compatibility and cost of the amplification process. In order to improve the manufacturing process, optimization studies have been carried out to evaluate the thickness, composition and pore size of the film type, all of which affect the temperature about the optimal drying time, and the ability of the material used in the absorbing coating process. These optimization processes and determinations are completely within the skills of those skilled in the art and are conventional. In order to develop a functional prototype for the U-DETECT test, the dry reagent test strip development is carried out in two stages.

[0146] Liquid assay is to the optimization of dry reagent test strip conversion.Optimization work begins by screening the material (reagent pad matrix) with different thickness, pore size and composition.This screening will help to identify the drying time with improvement, sample hydration ability (reagent pad must keep hydration during reaction time) and the signal change about background noise to keep the material with respect to the sensitivity of the assay form.From this screening, select minimum two materials, to move into the drying condition optimization.Reducing drying time will greatly affect future scale-up process and help to reduce manufacturing costs, therefore, it is equally important to identify the optimum temperature, which significantly reduces drying time to less than 30 minutes.Finally, by modifying the concentration of target probe such as BAD-5835 and modifying buffer pH (it may be the contributor of background noise), further study makes the background noise generated to be minimized (referring to Fig. 8).

[0147] Further optimization studies were performed with the test strips of the simulated DETECT assay wells, wherein the sample wells contained one or more BAD probes, BAPA and papain, and the control wells contained only BAPA and papain. Further optimization studies were performed with dBAPA, which can provide faster result time. On the one hand, it will be ensured that dBAPA does not become turnover during the manufacturing step due to its reactivity with papain. Detection limit studies were performed to check the % reduction in sensitivity of the recombinant target biomarker. Further studies were performed to determine the feasibility of replacing the p-nitroaniline of BAPA with a chromophore of a higher wavelength (525nm or 625nm).

[0148] Prototyping and Validation of the U-DETECT Test. The parameters established in the Phase 1 optimization work will be used to develop a functional prototype test strip that includes sample and control reagent pads in one test strip. During this prototyping phase, accelerated thermal stability testing of the test strips was performed at 2°C, 22°C, 37°C, and 45°C, with the test strips being assayed in triplicate once a week and compared to a baseline (2°C - Day 0). In order to determine the level of flexibility the U-DETECT test has, sample application studies were conducted. These studies will help determine whether dipping the test strip into the sample of interest has an effect on the analysis compared to sample addition via a pipette. In order to establish dipping as an application method, the dipping incubation time needs to be determined, as well as the removal of excess sample prior to instrument reading.

[0149] Once the parameters for the functional prototype had been determined (i.e., dual reagent pads on a single test strip, information about the stability of the test strip, and information about sample application), a validation study was performed with a panel of 96 bacterial clinical isolates to ensure sensitivity and specificity. DETECT scores greater than a threshold were considered positive, and the sensitivity and specificity of the modified assay were determined by analyzing the DETECT signal via a receiver operating characteristic (ROC) curve analysis. Accordingly, U-DETECT provides improved outcomes for patients with cUTI by immediately providing actionable information to guide appropriate antibiotic therapy. The development of such tests improves patient outcomes by informing early treatment decisions, enabling patients to receive the right care more quickly. This prevents disease progression to urosepsis, which has a mortality rate of 25–60% and imposes a significant economic burden on the healthcare system. While the initial target condition is UTI, the development of the U-DETECT test strip will allow for rapid detection of ceftriaxone resistance in blood and other sample types that are collected for diagnosis of a variety of disease conditions. As such, the market opportunity extends far beyond the initial UTI market to low- and middle-income countries (LMICs).

[0150] It will be understood that various modifications can be made without departing from the spirit and scope of the present disclosure. Accordingly, other implementations are within the scope of the following claims.

Claims

1. A solid matrix comprising reagents or components for measuring the presence of β-lactamase produced by Gram-negative, Gram-positive or pathogenic β-lactam-resistant bacteria, the solid matrix comprising: a first pad on the solid substrate, comprising a targeted small molecule probe specifically acted upon by β-lactamase; Caged enzyme amplifiers; and small-molecule indicators that release chromophores activated by noncaged enzyme amplifiers.

2. The solid substrate according to claim 1, wherein the solid substrate comprises a second pad on the solid substrate comprising a caged enzyme amplifier; and a small molecule indicator that releases a chromophore activated by the non-caged enzyme amplifier, wherein the second pad does not comprise the targeted small molecule probe, Optionally, a third pad or more pads of reagents or components are included on the solid substrate.

3. A solid substrate according to claim 1 or 2, wherein the components of the first pad and / or the second pad are dry.

4. A solid substrate according to claim 1 or 2, wherein the first pad, the second pad and the optional third pad or more pads comprise an adsorbent or a plastic material.

5. The solid matrix according to claim 4, wherein the adsorbent material is selected from paper, adsorbent polymers, silica gel, glass fibers, zeolites or fabrics.

6. A solid matrix according to claim 5, wherein the paper is selected from cellulose, nitrocellulose, texelin or filter paper.

7. The solid substrate according to claim 4, wherein the plastic material is selected from the group consisting of high density polyethylene (HDPE), low density polyethylene (LDPE), polypropylene (PP), polyvinyl chloride (PVC), polycarbonate (PC), polysulfone (PSF), polystyrene (PS), Teflon (FEP) or Teflon (PFA).

8. A solid substrate according to any one of the preceding claims, wherein the solid substrate comprises paper or plastic.

9. The solid substrate according to any one of the preceding claims, wherein the solid substrate is a rectangular strip having a width of less than 10 mm.

10. The solid substrate according to any one of the preceding claims, wherein the targeting small molecule probe comprises a β-lactam group.

11. The solid substrate according to any one of the preceding claims, wherein when the targeted small molecule probe is acted upon by β-lactamase, the targeted small molecule probe releases a thiophenol group, which interacts with the caged enzyme amplifier to be released from the cage and activate the enzyme amplifier.

12. The solid substrate according to any one of the preceding claims, wherein the caged enzyme amplifier is a caged cysteine ​​protease.

13. A solid substrate according to claim 12, wherein the cysteine ​​protease is selected from the group consisting of papain, bromelain, cathepsin K, calpain, caspase-1, separase, adenovirus endopeptidase, pyroglutamyl peptidase I, sortase A, hepatitis C virus peptidase 2, Sindbis virus type nsP2 peptidase, dipeptidyl peptidase VI, deSI-1 peptidase, TEV protease, amidophosphoribosyltransferase precursor, gamma-glutamyl hydrolase, hedgehog protein and dmpA aminopeptidase.

14. The solid substrate according to any one of the preceding claims, wherein the caged enzyme amplifier is caged papain.

15. The solid substrate according to claim 14, wherein the caged papain has a structure of papain-SS-CH3.

16. A solid substrate according to any one of the preceding claims, wherein the small molecule indicator that releases a chromophore is N-benzoyl-DL-arginine-4-nitroanilide (BAPA) or a derivative thereof.

17. A solid matrix according to claim 16, wherein said derivative of BAPA comprises a chromophore group different from the p-nitroaniline group.

18. A solid matrix according to claim 16 or claim 17, wherein the derivative of BAPA comprises a dipeptide -X1X2- or a tripeptide -X1X2X3- in place of the arginine group of BAPA, wherein X1, X2 and X3 are each independently selected from any amino acid.

19. The solid substrate according to claim 18, wherein at least one of X1 to X3 is a hydrophobic amino acid.

20. The solid substrate according to claim 19, wherein at least one of X1 to X3 is phenylalanine.

21. A solid substrate according to any one of the preceding claims, wherein said chromophore is released from said chromophore-releasing small molecule indicator when subjected to said enzyme amplifier.

22. The solid substrate according to claim 21, wherein the chromophore absorbs light at a wavelength of 350 nm to 900 nm.

23. A solid substrate according to claim 22, wherein the chromophore is p-nitroaniline and absorbs light at a wavelength of about 405 nm.

24. The solid substrate according to claim 23, wherein the chromophore absorbs light at a wavelength of 520 nm to 600 nm.

25. A solid substrate according to claim 24, wherein the chromophore is resorufin.

26. The solid substrate according to any one of the preceding claims, wherein the solid substrate comprises a third pad attached to the solid substrate, comprising the enzyme amplifier; and the chromophore-releasing small molecule indicator activated by the enzyme amplifier.

27. A solid substrate according to any one of the preceding claims, wherein said solid substrate comprises a fourth pad attached to said solid substrate, comprising a reagent or component comprising a small molecule indicator of said released chromophore that is activated by said enzyme amplifier.

28. A solid matrix comprising reagents or components for measuring the presence of β-lactamase produced by Gram-negative, Gram-positive or pathogenic β-lactam-resistant bacteria, comprising: A solid matrix having the following (a) a first region or layer comprising a targeted small molecule probe selected from (i) a β-lactamase-activated probe; (ii) a caged enzyme amplifier; and (iii) one or two components of the group consisting of a small molecule indicator that releases a chromophore; and (b) a second region or layer comprising (i), (ii) and / or (iii) which are not in the first region.

29. A solid substrate according to claim 28, wherein the first region and the second region are linearly separated from each other along a path followed by wicking liquid.

30. The solid substrate according to claim 28, wherein the first region and the second region are layered on top of each other.

31. The solid substrate according to claim 28, wherein the solid substrate comprises a third region having the caged enzyme amplifier; and the small molecule indicator that releases the chromophore, but does not comprise the targeted small molecule probe; Optionally, a fourth region or more regions of reagents or components are included on the solid substrate.

32. A solid substrate according to claim 28 or 31, wherein the components of the first region, the second region or the third region are dry.

33. A solid substrate according to claim 28 or 31, wherein the components of the first region, second region or third region are absorbed or adsorbed onto the solid substrate or a material attached thereto.

34. A solid matrix according to claim 33, wherein the solid support or material is selected from paper, adsorbent polymers, plastic silica gel, glass fibre, zeolite or fabric.

35. A solid matrix according to claim 34, wherein the paper is selected from cellulose, nitrocellulose, texelin or filter paper.

36. A solid matrix according to claim 34, wherein the plastic material is selected from the group consisting of high density polyethylene (HDPE), low density polyethylene (LDPE), polypropylene (PP), polyvinyl chloride (PVC), polycarbonate (PC), polysulfone (PSF), polystyrene (PS), Teflon (FEP) or Teflon (PFA).

37. A solid substrate according to any one of claims 28 to 36, wherein the solid substrate comprises paper or plastic.

38. A solid substrate according to any one of claims 28 to 37, wherein the solid substrate is a rectangular strip having a width of less than 10 mm.

39. The solid substrate according to any one of claims 28 to 38, wherein the targeting small molecule probe comprises a β-lactam group.

40. The solid substrate according to any one of claims 28 to 39, wherein when the targeted small molecule probe is acted upon by β-lactamase, the targeted small molecule probe releases a thiophenol group, which interacts with the caged enzyme amplifier to be released from the cage and activate the enzyme amplifier.

41. A solid substrate according to any one of claims 28 to 40, wherein the caged enzyme amplifier is a caged cysteine ​​protease.

42. A solid substrate according to claim 41, wherein the cysteine ​​protease is selected from the group consisting of papain, bromelain, cathepsin K, calpain, caspase-1, separase, adenovirus endopeptidase, pyroglutamyl peptidase I, sortase A, hepatitis C virus peptidase 2, Sindbis virus type nsP2 peptidase, dipeptidyl peptidase VI, deSI-1 peptidase, TEV protease, amidophosphoribosyltransferase precursor, gamma-glutamyl hydrolase, hedgehog protein and dmpA aminopeptidase.

43. A solid substrate according to any one of claims 28 to 42, wherein the caged enzyme amplifier is caged papain.

44. A solid substrate according to claim 43, wherein the caged papain has the structure of papain-SS-CH3.

45. A solid substrate according to any one of claims 28 to 44, wherein the small molecule indicator that releases a chromophore is N-benzoyl-DL-arginine-4-nitroanilide (BAPA) or a derivative thereof.

46. ​​A solid matrix according to claim 45, wherein said derivative of BAPA comprises a chromophore group different from the p-nitroaniline group.

47. A solid matrix according to claim 45 or claim 46, wherein the derivative of BAPA comprises a dipeptide -X1X2- or a tripeptide -X1X2X3- in place of the arginine group of BAPA, wherein X1, X2 and X3 are each independently selected from any amino acid.

48. A solid substrate according to claim 47, wherein at least one of X1 to X3 is a hydrophobic amino acid.

49. A solid substrate according to claim 48, wherein at least one of X1 to X3 is phenylalanine.

50. The solid substrate according to any one of claims 28 to 49, wherein said chromophore is released from said chromophore-releasing small molecule indicator when subjected to said enzyme amplifier.

51. A solid substrate according to claim 50, wherein the chromophore absorbs light at a wavelength of 350 nm to 900 nm.

52. A solid substrate according to claim 51, wherein the chromophore is p-nitroaniline and absorbs light at a wavelength of about 405 nm.

53. A solid substrate according to claim 52, wherein the chromophore absorbs light at a wavelength of 520 nm to 600 nm.

54. A solid substrate according to claim 53, wherein the chromophore is resorufin.

55. A method for measuring the presence of a β-lactamase produced by a pathogen in a sample, comprising: contacting a solid matrix according to any one of the preceding claims with the sample; The absorbance is measured at a wavelength of 400 nm to 600 nm, wherein a change in the measured absorbance of the solid matrix indicates the presence of a β-lactamase produced by a pathogen in the sample.

56. The method according to claim 55, wherein the beta-lactamase is selected from the group consisting of TEM-1, SHV-1, CTX-M-14, CTX-M-15, CMY-2 and KPC-2.

57. A method according to claim 55 or claim 56, wherein the pathogen is Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and / or Proteus mirabilis.

58. The method according to claim 55, wherein the sample is from a subject.

59. The method according to claim 55, wherein the sample is a urine or blood sample.

60. The method according to claim 55, wherein the sample is a urine sample from a subject suspected of having a urinary tract infection.

61. A solid substrate or method according to any one of the preceding claims, wherein the targeted small molecule probe has the general structure of Formula I: or a salt, stereoisomer, tautomer, polymorph or solvate thereof, in: T 1 is a group containing benzenethiol; Z 1 is a carboxylate, a carbonyl, or an ester; X 1 yes Y 1 yes R 1 -R 6 each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl, and optionally substituted heterocycle; R 7 is optionally substituted (C5-C7)cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle.

62. A solid matrix or method according to any one of the preceding claims, wherein T 1 is a benzenethiol group selected from the group consisting of:

63. A solid matrix or method according to claim 61, wherein R 7 Selected from the group consisting of:

64. A solid substrate or method according to claim 61, wherein the compound has the structure of Formula I(a): or a salt, stereoisomer, tautomer, polymorph or solvate thereof, wherein: T 1 It is a group containing benzenethiol; Z 1 is a carboxylate, a carbonyl, or an ester; X 1 yes Y 1 yes R 1 -R 6 each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl, and optionally substituted heterocycle; R 7 is optionally substituted (C5-C7)cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle.

65. A solid matrix or method according to claim 64, wherein T 1 is a benzenethiol group selected from the group consisting of:

66. A solid matrix or method according to claim 64, wherein R 7 Selected from the group consisting of:

67. A solid substrate or method according to claim 61, wherein the compound has the structure of Formula I(b): X 1 yes Y 1 yes R 1 -R 6 each independently selected from H, D, hydroxy, nitrile, halogen, amine, nitro, amide, thiol, aldehyde, carboxylic acid, alkoxy, optionally substituted (C1-C4) ester, optionally substituted (C1-C4) ketone, optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6) alkenyl, optionally substituted (C1-C6) alkynyl, optionally substituted (C5-C7) cycloalkyl, optionally substituted aryl, optionally substituted benzyl, and optionally substituted heterocycle; R 7 is optionally substituted (C5-C7)cycloalkyl, optionally substituted aryl, optionally substituted benzyl or optionally substituted heterocycle.

68. A solid matrix or method according to claim 67, wherein T 1 is a benzenethiol group selected from the group consisting of:

69. A solid matrix or method according to claim 67, wherein R 7 Selected from the group consisting of:

70. A solid matrix or method according to claim 61, wherein the compound is selected from the group consisting of: , or a salt, stereoisomer, tautomer, polymorph or solvate thereof.